@article{9f5192ff2a5e43b0ba8adefe599c126c,
title = "Frontline Management of Waldenstr{\"o}m Macroglobulinemia with Chemoimmunotherapy",
keywords = "Alkylating agents, IgM lymphoplasmacytic lymphoma, Limited-duration treatment, Monoclonal antibodies, Purine analogs",
author = "Prashant Kapoor and Jonas Paludo and Abeykoon, {Jithma P.}",
note = "Funding Information: P. Kapoor is the principal investigator of trials for which Mayo Clinic has received research funding from Amgen, United States , Regeneron, United States , Bristol Myers Squibb, United States , Loxo Pharmaceuticals , Ichnos , Karyopharm , Sanofi, United States , AbbVie and GlaxoSmithKline . P. Kapoor has served on the Advisory Boards of BeiGene, Pharmacyclics, X4 Pharmaceuticals, Kite, Oncopeptides, Angitia Bio, GlaxoSmithKline, AbbVie, and Sanofi. J. Paludo reports Honoraria to institution: Abbvie and research funding to institution: Karyopharm and Biofourmis . J. Abeykoon reports research funding from Qurient therapeutics.",
year = "2023",
month = aug,
doi = "10.1016/j.hoc.2023.04.003",
language = "English (US)",
volume = "37",
pages = "671--687",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",
}